Võrdle meetodeid
Vaata valitud meetodeid kõrvuti; erinevad read on esile tõstetud.
| PRISMA: Eelistatud süstemaatiliste ülevaadete ja metaanalüüside aruandlusüksused× | Võrkelementanalüüs× | |
|---|---|---|
| Valdkond≠ | Metaanalüüs | Tõendite süntees |
| Perekond | Process / pipeline | Process / pipeline |
| Tekkeaasta≠ | 2021 | 2002 |
| Looja≠ | Matthew Page et al. (PRISMA 2020) | Lumley (2002) |
| Tüüp≠ | Reporting guideline and flow diagram | Method |
| Algallikas≠ | Page, M. J., et al. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, 372, n71. DOI ↗ | Lumley, T. (2002). Network meta-analysis for indirect treatment comparisons. Statistics in Medicine, 21(16), 2313–2324. DOI ↗ |
| Rööpnimetused≠ | Preferred Reporting Items for Systematic Reviews and Meta-Analyses, PRISMA 2020, PRISMA checklist, Sistematik Derleme Raporlama Kılavuzu | Mixed Treatment Comparison, MTC, Indirect Comparison Meta-Analysis |
| Seotud≠ | 2 | 1 |
| Kokkuvõte≠ | PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) is a standardized reporting guideline designed to improve the transparency and completeness of systematic reviews and meta-analyses. Introduced in its current form by Page et al. in 2021 as PRISMA 2020, it provides a 27-item checklist and a four-phase flow diagram that together ensure every stage of a review — from database searching through final inclusion — is documented and reproducible. | Network meta-analysis (NMA) is a systematic method for comparing multiple interventions simultaneously within a single analytical framework, incorporating both direct evidence (head-to-head trials) and indirect evidence (comparisons via common comparators). First formalized by Lumley in 2002, NMA allows researchers to rank treatments and quantify comparative effectiveness even when some treatment pairs have never been directly studied. |
| ScholarGateAndmestik ↗ |
|
|